

Olaparib

Catalog No: tcsc0075



Available Sizes

Size: 10mg

Size: 50mg

Size: 100mg

Size: 200mg

Size: 500mg

Size: 1g

Size: 2g

Size: 5g

Size: 10g



Specifications

CAS No:
763113-22-0

Formula:
 $C_{24}H_{23}FN_4O_3$

Pathway:
Epigenetics;Cell Cycle/DNA Damage;Autophagy;Autophagy

Target:
PARP;PARP;Autophagy;Mitophagy

Purity / Grade:
>98%

Solubility:

DMSO : ≥ 33.33 mg/mL (76.72 mM)

Storage Instruction:

Powder
 -20°C 3 years
 4°C 2 years
 In solvent
 -80°C 6 months
 -20°C 1 month

Alternative Names:

AZD2281; KU0059436

Observed Molecular Weight:

434.46



Product Description



Olaparib (AZD2281; KU0059436) is a potent and oral **PARP** inhibitor with **IC₅₀**s of 5 and 1 nM for **PARP1** and **PARP2**, respectively.

IC50 & Target: IC50: 5/1 nM (PARP-1/2)^[1]

In Vitro: Olaparib (AZD2281) is a single digit nanomolar inhibitor of both PARP-1 and PARP-2 that shows standalone activity against BRCA1-deficient breast cancer cell lines. Olaparib is applied to SW620 cell lysates, and identified the IC₅₀ for PARP-1 inhibition to be around 6 nM and the total ablation of PARP-1 activity to be at concentrations of 30–100 nM^[1].

In Vivo: Animals bearing SW620 xenografted tumors are treated with Olaparib (10 mg/kg, p.o.) in combination with Temozolomide (TMZ) (50 mg/kg, p.o.) once daily for 5 consecutive days, after which the tumors are left to grow out^[1]. Olaparib increases vascular perfusion in Calu-6 tumors established in a DWC model. Administration of olaparib (50 mg/kg, p.o.) as a single agent (top panel) or in combination with radiation (bottom panel) results in an increase in fluorescence intensity in the Calu-6 tumors^[2].





All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!